Split Butterfly Valve: 30 Years of Innovation
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
The Technology That Changed Everything
Before 1988, pharmaceutical manufacturers faced a dangerous paradox: as drug compounds became more potent, the methods for handling them remained dangerously primitive. Operators charged reactors using glovebags, manually scooped powders between vessels, and relied on improvised adapters that leaked with every connection.
The industry needed a fundamental solution—not another workaround, but a true engineering breakthrough. That solution came from Andocksysteme: the Split Butterfly Valve.
Today, the Split Butterfly Valve (SBV) is the recognized standard for pharmaceutical containment interfaces, with thousands of installations worldwide across leading pharmaceutical manufacturers, CDMOs, and specialty chemical producers. But the journey from concept to global adoption is a story of engineering persistence, customer collaboration, and continuous innovation.
This is that story.
STAGE 1 - THE CHALLANGE
[Visual: Historical photo – pharmaceutical operator with glovebag/manual handling, or diagram showing exposure risk]
The Containment Crisis of the 1980s
In the late 1980s, pharmaceutical manufacturing was entering a new era. Active Pharmaceutical Ingredients (APIs) were becoming exponentially more potent—oncology drugs, hormones, and immunosuppressants that were effective in microgram doses but toxic to workers at the same concentrations.
The exposure problem was worst at connection points:
- Charging APIs into reactors
- Discharging mills and dryers
- Connecting mobile containers to process equipment
- Sampling intermediate materials
Traditional methods failed:
- Glovebags: Single-use plastic bags taped over flanges—prone to tears, operator-dependent, labor-intensive
- Local Exhaust Ventilation (LEV): Controlled dust dispersion but didn’t prevent it
- Manual Techniques: Relied entirely on operator skill and discipline
- Open Flanges: Every connection exposed workers until the seal was complete
The Real Cost
These improvised methods created:
- Worker Health Risks: Chronic exposure to toxic compounds, long-term health consequences
- Regulatory Liability: Increasingly strict Occupational Exposure Limits (OELs) that existing methods couldn’t meet
- Product Contamination: Cross-contamination between products in multi-use facilities
- Operational Inefficiency: Slow, labor-intensive procedures limiting throughput
The pharmaceutical industry needed a mechanical solution—not a procedural one.
THE SOLUTION (ASBV MUT INVENTION & EVOLUTION)
[Visual: Side-by-side comparison diagram]
LEFT SIDE: Traditional Open Flange Connection
`❌ TRADITIONAL METHOD:
- Position open valve A above open valve B
- Bring them together (powder escapes during approach)
- Tighten bolts (hoping seal is perfect)
- Open valves (exposure already occurred)`
RIGHT SIDE: Split Butterfly Valve Concept
`✓ ANDOCKSYSTEME SBV:
- Two closed disc halves (Active + Passive)
- Lock them together mechanically (no flow yet)
- Rotate unified disc to open (contained transfer)
- Close, unlock, separate (both sides still closed)
The Breakthrough: 1988-1992, An Unexpected Inspiration
The solution came from an unlikely source: Russian military engineering. Decades earlier, a Russian engineer had developed a split-mechanism design for rapid connection/disconnection of sealed lines in military vehicles. The core principle was elegant: instead of trying to seal two open interfaces together, start with two closed halves that lock first, then open as a unified system.
Günter Untsch, founder of Andocksysteme, recognized the potential. Working closely with engineers at a major European pharmaceutical facility, he adapted this military concept to industrial valve technology.
The innovation: Cut a standard butterfly valve disc in half. Create two independent closures that could exist separately but operate as one when docked together.
The First Prototypes
Between 1988 and 1992, Andocksysteme developed the first working prototypes:
Design Challenges Solved:
- Sealing Geometry: Optimizing disc profiles and elastomer seals for powder containment (not liquid-tight, but dust-tight)
- Locking Mechanism: Developing reliable mechanical locks simple enough for operators to engage/disengage
- Rotation System: Engineering the shaft-through-seal arrangement that would become the SBV signature
- Material Compatibility: Selecting stainless alloys and seals that could withstand pharmaceutical cleaning agents
Early Testing: The prototypes were validated at a European pharmaceutical facility on non-critical applications:
- Charging excipients into blenders
- Discharging dried granules from tray dryers
- Sampling intermediate powders
Results exceeded expectations:
- Measurable reduction in airborne particulate vs. glovebags
- Faster operation than manual bag-in/bag-out techniques
- Repeatable performance across multiple cycles
The concept worked. But the real test was yet to come.
Industrial Validation: The Continuous Manufacturing Project (1995-2000)
[Visual: Photo of pharmaceutical manufacturing line or facility]
The Proving Ground
In the mid-1990s, a leading pharmaceutical manufacturer announced a transformative project: Continuous Manufacturing Technology (CMT)—a shift from traditional batch processing to continuous, high-throughput production.
CMT presented unprecedented demands:
- High-Frequency Transfers: Materials flowing continuously between process steps
- Automated Operation: No time for manual interventions
- Zero Downtime Tolerance: Every containment failure stopped the entire production line
- Regulatory Scrutiny: FDA and EMA inspectors would examine every detail
The Selection Decision
When this pharmaceutical company evaluated containment interface suppliers, they chose Andocksysteme’s ASBV as the primary containment technology throughout the CMT line.
Why?
- Proven prototype performance from years of field collaboration
- Only technology offering truly closed docking
- Local engineering support and customization capability
- Trust built through long-term partnership
The Validation
The CMT project put the ASBV through its toughest test:
- Thousands of dock/undock cycles over years of operation
- Automated interfaces with pneumatic actuation
- Continuous production environment with no room for failure
Performance Results: ✓ Containment consistently <10 µg/m³ (OEB 3-4 range)
✓ Minimal maintenance requirements
✓ FDA and EMA regulatory approval
✓ Zero catastrophic containment failures
This CMT success transformed Andocksysteme from a component supplier into a recognized technical partner for high-containment pharmaceutical engineering.
Global Adoption & Technical Evolution (2000-2020)
[Visual: World map showing installation locations, or timeline graphic]
By the early 2000s, the pharmaceutical industry was awakening to extreme containment demands:
- Occupational Exposure Limits (OELs) tightening to <1 µg/m³ (OEB 5) for highly potent APIs
- Regulatory enforcement intensifying across FDA, EMA, and global authorities
- HPAPI manufacturing expanding in oncology, hormones, and specialty therapeutics
The Split Butterfly Valve became the industry standard.
Major equipment manufacturers (Glatt, GEA, Hosokawa, Dec Group) began specifying ASBV interfaces on mills, dryers, reactors, and containment isolators. Pharmaceutical companies included ASBV ports in new facility architectural specifications—like electrical outlets, but for powder transfer.
Technical Refinement
The ASBV evolved continuously based on real-world operational feedback:
Mechanical Enhancements:
- Tolerance Compensation: Spring-loaded docking mechanisms absorbing ±14mm axial offset and ±3° angular misalignment—critical for mobile container connections where perfect alignment is impossible
- Seal Optimization: Extended service life elastomers and improved chemical resistance
- Automation Integration: Pneumatic actuators, position sensors, and PLC compatibility
Cleanability Focus:
- Hygienic Design: Eliminating product traps and dead volumes for GMP compliance
- WIP/CIP Capability: Automated Wash-In-Place and Clean-In-Place systems for multi-product facilities
- Quick Product Contact Part Removal: Operators can disassemble and clean disc assemblies in minutes
Performance Achievement:
- OEB 5 Validated: Proven for OEL <1 µg/m³ across numerous installations
- SMEPAC Tested: Standardized measurement confirming containment performance
- ATEX Certified: Explosion-proof variants for flammable powder applications
Product Family Expansion
To serve diverse pharmaceutical applications, Andocksysteme expanded beyond the core ASBV:
APORT (2012): Integrated process + containment valve—eliminating “double interface” leak paths by combining process isolation and containment in a single mechanical unit
ASAM (2015): Contained sampling systems—enabling in-process quality control without breaking containment
ACUBE/ACUBE-PRO (2018): Large-scale FIBC (Flexible Intermediate Bulk Container) containment—for bulk powder handling with integrated docking frames
Proven Excellence: Recent High-Containment Projects (2020-Present)
[Visual: Modern pharmaceutical facility photo or advanced manufacturing equipment]
Next-Generation Facilities
In recent years, pharmaceutical manufacturers have invested billions in advanced high-containment facilities designed for the most demanding applications:
- OEL requirements <0.1 µg/m³ (beyond OEB 5)
- Flexible multi-product capabilities
- Industry 4.0 digital integration
- Serving as regulatory model plants globally
Industry Leadership Confirmed:
Leading pharmaceutical companies with access to every containment technology vendor worldwide continue to select Andocksysteme ASBV systems for their most critical projects.
Why? ✓ Decades of proven performance at existing facilities
✓ Zero catastrophic containment failures across thousands of operational cycles
✓ Engineering trust built through long-term collaboration
✓ Technical confidence in achieving extreme OEL requirements
✓ Lifecycle reliability demonstrating 10-20 year service life
Recent Project Scope Examples:
- 90+ ASBV interfaces in single advanced facilities
- Applications: reactor charging, mill feeding, blender discharge, IBC docking, sampling
- Custom developments for specialized processes
- Full digital integration with modern process control systems
Industry Impact:
When the world’s leading pharmaceutical manufacturers—with unlimited budgets and access to every technology vendor—consistently choose ASBV for their most advanced facilities, it confirms what three decades of operation have proven: Andocksysteme’s Split Butterfly Valve is the global reference for pharmaceutical containment.
STAGE 3 - THE FUTURE (AVAX SUT & HYBRID APPROACH)
[Visual: AVAX product image or MUT vs. SUT comparison]
Single-Use Innovation: The AVAX Evolution, A New Market Challenge
By 2010, the pharmaceutical industry was evolving in new directions:
- Campaign-Based Manufacturing: Small-batch production for clinical trials, orphan drugs, and personalized medicine
- Cleaning Validation Complexity: Multi-product facilities struggling with residue limits and validation costs
- Flexibility Demands: Need to rapidly switch between products without extensive cleaning protocols
Traditional multi-use stainless steel ASBV systems remained ideal for long-term, high-throughput production. But for certain applications, cleaning complexity exceeded material handling complexity.
The industry needed a single-use alternative—but without sacrificing containment performance.
AVAX: Split Butterfly Valve Technology for Single-Use
[Visual: AVAX cutaway or installation photo]
The Innovation
In 2010, Andocksysteme launched AVAX: the world’s first single-use Split Butterfly Valve, bringing the same mechanical containment principles to disposable applications.
AVAX Technology:
- Disposable Product Contact Components: Pharmaceutical-grade plastics replacing stainless steel disc halves
- Same SBV Architecture: Two closed halves that dock, open together, transfer, close, and separate
- Bayonet Lock Design: Quick connection/disconnection for rapid campaign changeovers
- Gamma Sterilization Option: Pre-sterilized components for aseptic applications
- Hybrid Compatibility: AVAX passive sides can dock with ASBV active sides—standardizing interfaces across MUT and SUT applications
Key Applications: ✓ Clinical trial manufacturing (frequent product changes)
✓ Highly toxic APIs (eliminate cleaning validation burden)
✓ Allergens and beta-lactams (absolute cross-contamination prevention)
✓ Campaign-based production (short runs, high flexibility)
The Hybrid Strategy: Best of Both Worlds
[Visual: Comparison table – ASBV MUT vs. AVAX SUT vs. Hybrid approach]
Unlike competitors focused exclusively on one approach, Andocksysteme developed a unique hybrid philosophy:
Multi-Use (ASBV) When:
- Long production campaigns (months/years)
- High-throughput continuous operations
- Mature products with established cleaning validation
- Lower lifecycle cost priority
Single-Use (AVAX) When:
- Frequent product changeovers (days/weeks)
- Highly toxic compounds (OEB 5)
- Allergen segregation requirements
- Clinical/small-batch manufacturing
Hybrid Combination:
- Active side (reusable stainless) on fixed equipment (reactors, mills, dryers)
- Passive side (disposable) on mobile containers (IBCs, bins, drums)
- Result: Reduced plastic waste vs. all-disposable strategies while maintaining campaign flexibility
Sustainability Gains: Engineering for the Environment
[Visual: Infographic showing water/energy consumption comparison]
Beyond operational flexibility, the ASBV/AVAX hybrid approach delivers measurable sustainability benefits:
Water Conservation:
- Traditional All-Disposable Strategy: No cleaning water, but massive plastic waste (entire valve assemblies discarded per campaign)
- Traditional All-Reusable Strategy: Intensive CIP/WIP cycles consuming thousands of liters per cleaning
- Andocksysteme Hybrid Strategy: Clean permanent infrastructure (active sides) less frequently, replace only passive disc components
Estimated Water Savings: 40-60% reduction vs. all-reusable strategy in high-changeover facilities
Energy Efficiency:
- Reduced CIP/WIP Duration: Less time heating, circulating, and drying cleaning fluids
- Optimized Cleaning Protocols: Target cleaning only where necessary (product contact parts), not entire assemblies
- Lower HVAC Load: Shorter cleaning cycles mean less environmental control system runtime
Estimated Energy Savings: 30-50% reduction in cleaning-related energy consumption
Plastic Waste Reduction:
- vs. All-Disposable Competitors: Hybrid approach uses 60-70% less disposable plastic
- Reusable Infrastructure: Active valve bodies, frames, and automation last 15-20 years
- Targeted Disposal: Only product-contact disc components replaced, not entire valve assemblies
The Future: Continuous Innovation
[Visual: Future-looking graphic – digital integration, sustainability icons, emerging applications]
After more than 30 years, Andocksysteme continues active development of Split Butterfly Valve technology:
Digital Integration (2025-2027):
- IoT-enabled ASBV with predictive maintenance analytics
- Real-time containment performance monitoring
- Integration with Industry 4.0 / MES systems
Advanced Materials:
- Next-generation elastomers for extreme chemical resistance
- Extended temperature range capabilities (-50°C to +200°C)
- Bio-based and compostable materials for SUT components
Emerging Applications:
- Battery Materials Manufacturing: Lithium compounds, graphite, cathode materials (OEL ~1-10 µg/m³, ATEX Zone 21/22)
- Specialty Chemicals: REACH SCC driving pharmaceutical-style containment in fine chemicals
- Advanced Materials: Semiconductors, quantum computing materials, nanomaterials
Sustainability Roadmap:
- Target: 100% recyclable or compostable SUT components by 2030
- Water usage reduction: 50% vs. 2020 baseline
- Carbon footprint: net-zero manufacturing by 2035
[Visual: Horizontal timeline – suggested placement at bottom of page]
`══════════════════════════════════════════════════════════════════════════
1988 1995 2005 2020 2025+ | | | | | ● SBV CONCEPT ● CMT PROJECT ● GLOBAL ● ADVANCED ● INDUSTRY 4.0 Breakthrough Industrial ADOPTION FACILITIES INTEGRATION idea born validation OEB 5 proven Next-gen plants Digital/AI
2010 2012 2022 Future
| | | |
● AVAX LAUNCH ● APORT ● 30 YEARS ● SUSTAINABILITY
Single-use Integration 3,000+ Net-zero
innovation breakthrough installations roadmap`
SECTION 7: PRODUCT COMPARISON TABLE
[Visual: Table comparing Early ASBV vs. Modern ASBV vs. AVAX]
| Feature | Early ASBV (1992) | Modern ASBV (2025) | AVAX (2010+) |
|---|---|---|---|
| Containment Performance | <10 µg/m³ (OEB 3-4) | <0.1 µg/m³ (OEB 5+) | <1 µg/m³ (OEB 5) |
| Size Range | DN100-DN200 | DN50-DN300+ | DN100-DN150 |
| Service Life | 5-7 years | 15-20 years | Single campaign (disposable) |
| Tolerance Compensation | ±5mm axial | ±14mm axial / ±3° angular | ±10mm axial |
| Automation | Manual operation | Pneumatic + PLC | Manual/pneumatic |
| Cleaning | Manual WIP | Automated CIP/WIP | No cleaning (disposable) |
| Material | Stainless 316L | Stainless 316L + advanced seals | Pharmaceutical-grade plastics |
| Applications | API production | API + galenic + chemicals | Clinical trials, allergens, campaigns |
30 Years Proven. Still Innovating
From the first prototype in 1988 to today’s advanced pharmaceutical facilities, the Split Butterfly Valve has remained the global standard for pharmaceutical containment because Andocksysteme never stopped engineering.
Explore Our Complete SBV Portfolio:
[Button: ASBV Multi-Use Technology →] /en/products/asbv/
[Button: AVAX Single-Use Technology →] /en/products/avax/
[Button: Download Technical Documentation →] [PDF link]
Need Application Support?
Our engineering team can help you select the optimal containment strategy for your facility.
[Button: Contact Engineering →] /en/contact/